Filters








727 Hits in 0.69 sec

Controversies in treating bipolar depression

Stephen M. Stahl
2013 CNS Spectrums  
Stephen M.  ...  Stahl Editor-in-Chief CNS Spectrums, Department of Psychiatry University of California-San Diego, San Diego California and Department of Psychiatry, University of Cambridge Cambridge, UK https://www.cambridge.org  ... 
doi:10.1017/s1092852913000448 pmid:23866090 fatcat:qdrigtqrxjer5gqpkqodgmxpj4

Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?

Stephen M. Stahl
2016 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852916000742 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852916000742 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852916000742 pmid:27855728 fatcat:jx6z7xigunddpo56elmje3ghzq

Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice

Stephen M. Stahl
2017 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S109285291600095X Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S109285291600095X Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s109285291600095x pmid:28168945 fatcat:dp6uwscarnd5pormual6ewi56e

Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?

Stephen M. Stahl
2018 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918001219 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918001219 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852918001219 pmid:30160230 fatcat:oqj45xtygvfsvh3xkllwafliey

Mechanism of action of brexpiprazole: comparison with aripiprazole

Stephen M. Stahl
2016 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852915000954 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852915000954 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852915000954 pmid:26899451 fatcat:jevjbvz6fvdtlcmwzmx3pkmn2m

Focus on Antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?

Stephen M. Stahl
2004 International Journal of Neuropsychopharmacology  
Dr Stahl is a Field Editor of the International Journal of Neuropsychopharmacology. He was not involved in the review of this paper.  ...  Statement of Interest Dr Stahl has served as a consultant, received honoraria from, or conducted clinical research supported by the following : Abbott Laboratories, Asahi Kasei, AstraZeneca Pharmaceuticals  ...  , 1999b (Stahl, ,c, 2002a Stahl and Grady, In Press) .  ... 
doi:10.1017/s1461145704004146 pmid:14984629 fatcat:wy7jsshbirhdjcy4kekltx6zaq

Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough

Stephen M. Stahl
2018 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918000858 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918000858 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852918000858 pmid:29676241 fatcat:b4tb2fup75hcbewzchvvmy7n5m

New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis

Stephen M. Stahl
2018 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918001360 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852918001360 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852918001360 fatcat:jdmby7youngaxav5j2dhmwlrca

Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology

Stephen M Stahl
2010 Neuropsychopharmacology  
DISCLOSURE Over the past 12 months (January 2009-January 2010), Dr Stahl  ...  Information processing by these circuits following such a provocative load can then be quantified using various imaging (Fineberg et al, 2010; Stahl, 2008; Bush et al, 2005) or electrophysiological techniques  ...  and trouble concentrating may map to the DLPFC, whereas emotional symptoms such as mood and anxiety map to the amygdala and pgACC (Salvadore et al, 2009 (Salvadore et al, , 2010 Fineberg et al, 2010; Stahl  ... 
doi:10.1038/npp.2010.29 pmid:20463680 pmcid:PMC3055455 fatcat:5avordcjmvglpcghzvzd7blvuq

Methylated spirits: epigenetic hypotheses of psychiatric disorders

Stephen M Stahl
2010 CNS Spectrums  
D o w n s t r e a m , t h e c o n s p i r a c y d e e p e n s .  ...  Stahl SM. CNS Spectr.  ... 
pmid:20414171 fatcat:itkfb4cyxre7zanan22qdvdqge

Serotonergic mechanisms and the new antidepressants

Stephen M. Stahl
1993 Psychological Medicine  
STEPHEN M. STAHL Table 1 . 1 Serotonin selective reuptake inhibitors Table 2.  ...  , 1992; Stahl et al. 1992) .  ... 
doi:10.1017/s0033291700028348 fatcat:2edwair2pbdtjcavvz3lnm3rny

Finding what you are not looking for: Strategies for developing novel treatments in psychiatry

Stephen M. Stahl
2006 NeuroRx  
Psychopharmacological treatments in psychiatry are often surprises. Original targets frequently fail, and when successful, may only be the opening volley in a series of ever more important therapeutic applications. Drug development may begin by hypothesis-driven targeting of therapeutic indications with an agent of known and novel mechanism of action. Although this may generate a highly feasible therapeutic indication and can proceed by a well-worn regulatory pathway with known approvable
more » ... wn approvable endpoints, it may not only be the least innovative but also the least commercially successful strategy. Because surrogate markers of efficacy are only theoretically attractive but still largely elusive for psychiatric disorders, drug development strategies may need to proceed instead by opportunistic capturing of signals from clinical use of new agents once they enter clinical practice. Outcomes and dosing for clinical trial populations may not match those in clinical practice, so observations from clinical practice must feed back into new clinical trials. In many ways, once efficacy is proven for the originally targeted indication, drug development begins afresh. To get to secondary stages of novel indications for psychiatric drugs and thus to maximize each drug's therapeutic potential, evidencebased prescribing is followed by prescribing-based evidence, namely feedback from clinical practice into clinical proof-of-concept studies followed by large-scale studies and new indications. In many cases, the new indications are the more important therapeutic contributions and the most successful commercial application of a drug. Here we describe this strategy of psychiatric drug development and provide numerous examples.
doi:10.1016/j.nurx.2005.12.002 pmid:16490409 pmcid:PMC3593354 fatcat:4ix4jp2mqvaohperqs6at5lzlm

Long-acting injectable antipsychotics: shall the last be first?

Stephen M. Stahl
2014 CNS Spectrums  
Stephen M.  ...  Stahl ISSUE: A paradigm shift is afoot in which the ''last shall be first,'' namely, use of longacting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia  ... 
doi:10.1017/s1092852913001016 pmid:24512639 fatcat:4wjs3drggbdxfiq2kcdxrbh7ia

Kick-off editorial for 2014: Thanks to our reviewers

Stephen M. Stahl
2014 CNS Spectrums  
M. STAHL https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852913001028 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852913001028 fatcat:gyudxhdr7fdubd5db7bxnof7le

Mixed-up about how to diagnose and treat mixed features in major depressive episodes

Stephen M. Stahl
2017 CNS Spectrums  
M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852917000207 Downloaded from https://www.cambridge.org/core.  ...  M. Stahl BRAINSTORMS-Clinical Neuroscience Update https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852917000207 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s1092852917000207 pmid:28271818 fatcat:zo54ko6oozhdfigogg5sic3bku
« Previous Showing results 1 — 15 out of 727 results